212 related articles for article (PubMed ID: 19114881)
1. Systemic use of the endolysin Cpl-1 rescues mice with fatal pneumococcal pneumonia.
Witzenrath M; Schmeck B; Doehn JM; Tschernig T; Zahlten J; Loeffler JM; Zemlin M; Müller H; Gutbier B; Schütte H; Hippenstiel S; Fischetti VA; Suttorp N; Rosseau S
Crit Care Med; 2009 Feb; 37(2):642-9. PubMed ID: 19114881
[TBL] [Abstract][Full Text] [Related]
2. Delivery of the endolysin Cpl-1 by inhalation rescues mice with fatal pneumococcal pneumonia.
Doehn JM; Fischer K; Reppe K; Gutbier B; Tschernig T; Hocke AC; Fischetti VA; Löffler J; Suttorp N; Hippenstiel S; Witzenrath M
J Antimicrob Chemother; 2013 Sep; 68(9):2111-7. PubMed ID: 23633685
[TBL] [Abstract][Full Text] [Related]
3. Phosphodiesterase 2 inhibition diminished acute lung injury in murine pneumococcal pneumonia.
Witzenrath M; Gutbier B; Schmeck B; Tenor H; Seybold J; Kuelzer R; Grentzmann G; Hatzelmann A; van Laak V; Tschernig T; Mitchell TJ; Schudt C; Rosseau S; Suttorp N; Schütte H
Crit Care Med; 2009 Feb; 37(2):584-90. PubMed ID: 19114892
[TBL] [Abstract][Full Text] [Related]
4. Low-dose aerosol model of pneumococcal pneumonia in the mouse: utility for evaluation of antimicrobial efficacy.
Nuermberger E; Helke K; Bishai WR
Int J Antimicrob Agents; 2005 Dec; 26(6):497-503. PubMed ID: 16289711
[TBL] [Abstract][Full Text] [Related]
5. Phage lytic enzymes as therapy for antibiotic-resistant Streptococcus pneumoniae infection in a murine sepsis model.
Jado I; López R; García E; Fenoll A; Casal J; García P;
J Antimicrob Chemother; 2003 Dec; 52(6):967-73. PubMed ID: 14613958
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of pulsatile amoxicillin and clarithromycin dosing alone and in combination in a murine pneumococcal pneumonia model.
Sun HK; Lee SY; Banevicius MA; Du X; Maglio D; Nicolau DP
J Antimicrob Chemother; 2005 Sep; 56(3):559-65. PubMed ID: 16024590
[TBL] [Abstract][Full Text] [Related]
7. Local activation of the tissue factor-factor VIIa pathway in patients with pneumonia and the effect of inhibition of this pathway in murine pneumococcal pneumonia.
Rijneveld AW; Weijer S; Bresser P; Florquin S; Vlasuk GP; Rote WE; Spek CA; Reitsma PH; van der Zee JS; Levi M; van der Poll T
Crit Care Med; 2006 Jun; 34(6):1725-30. PubMed ID: 16625114
[TBL] [Abstract][Full Text] [Related]
8. Cefuroxime for empiric treatment of community-acquired pneumococcal pneumonia: is there a generation gap?
Wiener-Well Y; Raveh D; Schlesinger Y; Yinnon AM; Rudensky B
Chemotherapy; 2009; 55(2):97-104. PubMed ID: 19145079
[TBL] [Abstract][Full Text] [Related]
9. Effects of specific neutrophil elastase inhibitor, sivelestat sodium hydrate, in murine model of severe pneumococcal pneumonia.
Yanagihara K; Fukuda Y; Seki M; Izumikawa K; Miyazaki Y; Hirakata Y; Tsukamoto K; Yamada Y; Kamhira S; Kohno S
Exp Lung Res; 2007 Mar; 33(2):71-80. PubMed ID: 17454103
[TBL] [Abstract][Full Text] [Related]
10. Pulmonary damage and bacterial load in assessment of the efficacy of simulated human treatment-like amoxicillin (2,000 milligrams) therapy of experimental pneumococcal pneumonia caused by strains for which amoxicillin MICs differ.
Gracia M; Martínez-Marín C; Huelves L; Giménez MJ; Aguilar L; Carcas A; Ponte C; Soriano F
Antimicrob Agents Chemother; 2005 Mar; 49(3):996-1001. PubMed ID: 15728894
[TBL] [Abstract][Full Text] [Related]
11. [Pneumococcal pneumonia resistant to penicillin].
Garrait V; Vassal T; Barakett V; Guidet B; Offenstadt G
Rev Pneumol Clin; 1991; 47(5):214-6. PubMed ID: 1805338
[TBL] [Abstract][Full Text] [Related]
12. Effect of anesthetics on pathogenesis of experimentally induced murine pneumococcal pneumonia.
Rubins JB; Charboneau D
Comp Med; 2000 Jun; 50(3):292-5. PubMed ID: 10894495
[TBL] [Abstract][Full Text] [Related]
13. Role of pneumolysin for the development of acute lung injury in pneumococcal pneumonia.
Witzenrath M; Gutbier B; Hocke AC; Schmeck B; Hippenstiel S; Berger K; Mitchell TJ; de los Toyos JR; Rosseau S; Suttorp N; Schütte H
Crit Care Med; 2006 Jul; 34(7):1947-54. PubMed ID: 16715037
[TBL] [Abstract][Full Text] [Related]
14. Recombinant activated protein C attenuates coagulopathy and inflammation when administered early in murine pneumococcal pneumonia.
Schouten M; van 't Veer C; Roelofs JJ; Gerlitz B; Grinnell BW; Levi M; van der Poll T
Thromb Haemost; 2011 Dec; 106(6):1189-96. PubMed ID: 21901240
[TBL] [Abstract][Full Text] [Related]
15. Ceftriaxone pharmacokinetics in interleukin-10-treated murine pneumococcal pneumonia.
Wang E; Bergeron Y; Bergeron MG
J Antimicrob Chemother; 2005 May; 55(5):721-6. PubMed ID: 15772139
[TBL] [Abstract][Full Text] [Related]
16. A novel chimeric phage lysin with high in vitro and in vivo bactericidal activity against Streptococcus pneumoniae.
Díez-Martínez R; De Paz HD; García-Fernández E; Bustamante N; Euler CW; Fischetti VA; Menendez M; García P
J Antimicrob Chemother; 2015; 70(6):1763-73. PubMed ID: 25733585
[TBL] [Abstract][Full Text] [Related]
17. Establishment of a young mouse model and identification of an allelic variation of zmpB in complicated pneumonia caused by Streptococcus pneumoniae.
Hsieh YC; Tsao PN; Chen CL; Lin TL; Lee WS; Shao PL; Lee CY; Hsueh PR; Huang LM; Wang JT
Crit Care Med; 2008 Apr; 36(4):1248-55. PubMed ID: 18379252
[TBL] [Abstract][Full Text] [Related]
18. Acute phase response impairs host defense against Pseudomonas aeruginosa pneumonia in mice.
Renckens R; van Westerloo DJ; Roelofs JJ; Pater JM; Schultz MJ; Florquin S; van der Poll T
Crit Care Med; 2008 Feb; 36(2):580-7. PubMed ID: 18091542
[TBL] [Abstract][Full Text] [Related]
19. Anti-tumor necrosis factor antibody impairs the therapeutic effect of ceftriaxone in murine pneumococcal pneumonia.
Rijneveld AW; Florquin S; Hartung T; Speelman P; van der Poll T
J Infect Dis; 2003 Jul; 188(2):282-5. PubMed ID: 12854084
[TBL] [Abstract][Full Text] [Related]
20. Severe pneumococcal pneumonia: new strategies for management.
Chiou CC; Yu VL
Curr Opin Crit Care; 2006 Oct; 12(5):470-6. PubMed ID: 16943728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
